| abstract |
The present invention relates to a novel polyethylene glycol (PEG)-based adrenomedullin prodrug, to a process for its preparation, to its use for the treatment and/or prevention of diseases, and to its use for the preparation of adrenomedullin for the treatment and/or prevention Use of a medicament for a disease, especially a cardiovascular disorder, an edematous disorder and/or an inflammatory disorder. |